Skip to content

Entacapone

    Brands

    DEA Class;  Rx

    Common Brand Names; Comtan

    • Antiparkinson Agents, COMT Inhibitors
    Reversible peripheral COMT inhibitor; improves levodopa availability in the CNS
    Used for adults with Parkinson’s disease as an adjunct to levodopa/carbidopa
    Increased levodopa-induced side effects may be seen during initial therapy; shorter COMT inhibition but improved side effect profile compared to tolcapone

    Indicated for use as an adjunct to levodopa and carbidopa to treat end-of-dose ‘wearing-off’ in patients with Parkinson’s disease.

    Hypersensitivity to drug or excipients

    Consult your pharmacist or physician.

    Use only in combo with levodopa/carbidopa

    Not for coadministration with a non-selective MAO inhibitor; monoamine oxidase and catechol-0-methyltransferase (COMT) are both involved in the metabolism of catecholamines as the combination of this drug and a non-selective MAO inhibitor (eg, phenelzine and tranylcypromine) could inhibit the majority of the pathways responsible for normal catecholamine metabolism; however, it may be taken with a selective MAO-B inhibitor, including selegiline

    Dopaminergic therapy in Parkinson’s disease patients has been associated with orthostatic hypotension; the drug enhances levodopa bioavailability and, therefore, might be expected to increase occurrence of orthostatic hypotension; syncope reported more frequently in patients with documented hypotension

    This drug may potentiate dopaminergic side effects of levodopa and may cause or exacerbate preexisting dyskinesia; although decreasing the dose of levodopa may ameliorate this side effect, many patients in controlled studies continued to experience frequent dyskinesia despite a reduction in their dose of levodopa

    Pregnancy Category: C

    Lactation: excretion in milk unknown; use with caution

    Adults

    1,600 mg/day PO. Limited data are available for doses more than 1,600 mg/day.

    Geriatric

    1,600 mg/day PO. Limited data are available for doses more than 1,600 mg/day.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Not indicated.

    entacapone

    tablet

    • 200mg